BioInvent achieved solid progress throughout the third quarter, and CEO Martin Welschof anticipates a data-rich conclusion to 2024 that will further strengthen the company.– Looking ahead to next year, we expect BioInvent’s strong momentum to persist, with seven essential data readouts across four drug candidates in clinical development. Read the …
BioStock: BioInvent anticipates strong influx of clinical data
BioInvent achieved solid progress throughout the third quarter, and CEO Martin Welschof anticipates a data-rich conclusion to 2024 that will further strengthen the company.
– Looking ahead to next year, we expect BioInvent’s strong momentum to persist, with seven essential data readouts across four drug candidates in clinical development.
Read the article at biostock.se:
https://www.biostock.se/en/2024/10/bioinvent-anticipates-strong-influx-of-clinical-data/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
